Sunday, June 5, 2022, Chicago, Illinois, 6:45 AM – 7:45 AM Central Time (7:45 AM – 8:45 AM Eastern Time)

Breakfast with the Investigators: Ovarian Cancer

A CME Hybrid Symposium Held in Conjunction with the 2022 ASCO Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Program Schedule — Central Time
6:15 AM – 6:45 AM — Registration and Breakfast
6:45 AM – 7:45 AM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Antonio González-Martín, MD, PhD
Co-Director, Oncology Department
Cancer Center Director, Clínica Universidad de Navarra
Madrid, Spain

Joyce F Liu, MD, MPH
Associate Chief and Director of Clinical Research
Division of Gynecologic Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts


Kathleen N Moore, MD, MS
Virginia Kerley Cade Chair in Developmental Therapeutics
Associate Director for Clinical Research
Director, Early Phase Drug Development
Stephenson Cancer Center at the University of Oklahoma HSC
Professor, Section of Gynecologic Oncology
Associate Program Director, Gynecologic Oncology Fellowship
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, Mersana Therapeutics Inc, and Novocure Inc.
Program Schedule — Central Time
6:15 AM – 6:45 AM — Registration and Breakfast
6:45 AM – 7:45 AM — Educational Meeting

MODULE 1: First-Line Treatment Decision-Making for Patients with Advanced Ovarian Cancer (OC)

  • Incidence of germline and somatic BRCA mutations and homologous recombination deficiency (HRD) in patients with advanced OC; indications and optimal platforms for genetic testing
  • Key factors affecting treatment decision-making for patients with newly diagnosed advanced OC (eg, BRCA and/or HRD status, age and comorbidities, residual disease after surgery, type of and response to primary therapy)
  • Long-term efficacy and safety findings from Phase III studies supporting the use of olaparib, niraparib and olaparib/bevacizumab as maintenance therapy for newly diagnosed OC (eg, SOLO-1, PRIMA, PAOLA-1)
  • Findings from and clinical implications of the Phase II OVARIO study assessing maintenance with niraparib/bevacizumab after front-line platinum-based chemotherapy/bevacizumab for advanced OC
  • Anticipated results of the Phase III ATHENA-MONO study; potential role of rucaparib as first-line maintenance

MODULE 2: Management of Relapsed OC; Future Directions with PARP Inhibitor Therapy for Newly Diagnosed and Recurrent Disease

  • Long-term follow-up from pivotal clinical trials evaluating niraparib, olaparib and rucaparib for platinum-sensitive and platinum-resistant recurrent OC; patient- and disease-related factors in the selection of a PARP inhibitor
  • Key findings from the Phase IIIb OReO study evaluating the clinical utility of rechallenge with a PARP inhibitor for patients who have experienced disease progression on or after PARP inhibitor therapy; implications for later-line therapy
  • Available data from the Phase III ARIEL4 trial evaluating rucaparib versus chemotherapy for relapsed OC with BRCA mutations; outcomes in the subgroup of patients with BRCA reversion mutations and ramifications, if any, for routine practice
  • Biologic rationale for combining PARP inhibitors with anti-PD-1/PD-L1 antibodies with or without bevacizumab for OC; published results from early-phase studies evaluating these combinations (eg, MEDIOLA, TOPACIO, OPAL)
  • Design, eligibility criteria and primary and secondary endpoints of ongoing trials evaluating PARP inhibitors in combination with immune checkpoint inhibitors for advanced OC (eg, ATHENA-COMBO, FIRST, DUO-O, MOONSTONE)

MODULE 3: Other Novel Agents and Strategies Under Investigation for Advanced OC

  • Mechanism of action of mirvetuximab soravtansine; published research findings with mirvetuximab soravtansine alone or in combination with other systemic therapies (eg, bevacizumab) for platinum-resistant OC
  • Emerging results from the single-arm Phase III SORAYA study demonstrating a favorable response rate and duration of response with mirvetuximab soravtansine for patients with high folate receptor alpha platinum-resistant OC
  • Other ongoing studies of mirvetuximab soravtansine for platinum-resistant and platinum-sensitive OC (eg, MIRASOL, PICCOLO); potential clinical role
  • Spectrum, frequency and severity of toxicities, including ocular adverse events, reported with mirvetuximab soravtansine
  • Biologic rationale for targeting NaPi2b in OC; structural components and mechanism of antitumor activity of upifitamab rilsodotin (UpRi)
  • Available efficacy and safety findings with and ongoing evaluation of UpRi for platinum-resistant and platinum-sensitive OC
  • Mechanism of action of tumor treating fields (TTFs) and biologic rationale for their investigation in OC
  • Early-phase efficacy and safety data with and ongoing Phase III investigation of TTFs in combination with chemotherapy for advanced OC
  • Other promising novel agents and strategies for patients with advanced OC

Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of ovarian cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Consider available and emerging clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced OC, and counsel appropriate patients regarding personalized treatment recommendations.
  • Assess available clinical trial data with and approved indications for FDA-endorsed PARP inhibitors for recurrent, platinum-sensitive and multiregimen-refractory OC in order to optimally incorporate these agents into patient care.
  • Appreciate the biologic rationale for and published clinical research data with the use of PARP inhibitors in combination with other systemic therapies, and consider the clinical and research implications of these findings for current and future OC management.
  • Recognize the rationale for targeting folate receptor alpha and sodium-dependent phosphate transport protein 2b in OC, and consider available research findings with and the potential role of novel therapeutic approaches exploiting these biomarkers.
  • Describe the scientific rationale for the use of tumor treating fields (TTFs) as a therapeutic approach for OC, and appraise the available efficacy and safety data with TTFs in combination with chemotherapy for recurrent, advanced disease.
  • Recall the design of ongoing clinical trials evaluating novel agents and strategies for OC, and counsel appropriate patients about availability and participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr González-MartínAdvisory Committee and Consulting Agreements: Alkermes, Amgen Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genmab, GlaxoSmithKline, ImmunoGen Inc, MacroGenics Inc, Merck, Merck Sharp & Dohme LLC, Mersana Therapeutics Inc, Novartis, Oncoinvent, Pfizer Inc, PharmaMar, Roche Laboratories Inc, SOTIO LLC, Sutro Biopharma; Contracted Research: GlaxoSmithKline, Roche Laboratories Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, GlaxoSmithKline, Merck Sharp & Dohme LLC, PharmaMar, Roche Laboratories Inc. Dr LiuAdvisory Committee: AstraZeneca Pharmaceuticals LP, Eisai Inc, Epsila Bio, Genentech, a member of the Roche Group, GlaxoSmithKline, Regeneron Pharmaceuticals Inc; Consulting Agreement: Genentech, a member of the Roche Group. Dr MooreAdvisory Committee: Alkermes, Aravive Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Eisai Inc, Elevar Therapeutics, EMD Serono Inc, Genentech, a member of the Roche Group, Hengrui Therapeutics Inc, I-Mab Biopharma, ImmunoGen Inc, IMXmed, Lilly, Merck, Mereo BioPharma, Mersana Therapeutics Inc, Novartis, Onconova Therapeutics Inc, OncXerna Therapeutics Inc, Tarveda Therapeutics, Tesaro, A GSK Company, VBL Therapeutics; Consulting Agreement: AstraZeneca Pharmaceuticals LP; Contracted Research: Lilly, Merck, PTC Therapeutics; Data and Safety Monitoring Board/Committee: SQZ Biotech.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, Mersana Therapeutics Inc, and Novocure Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

Directions:
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of ovarian cancer.

There is no fee to participate in this program or live webcast of this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.

Registration for in-person meeting

In order to attend this in-person event, please register here.

Registration for event »
 
Registration for live webcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.